Key result
Low-dose pemafibrate (0.1 mg/day) significantly decreased triglyceride levels by a mean of 90.6 mg/dL compared to baseline in patients with type 2 diabetes and hypertriglyceridemia.
Why the study?
Pemafibrate is a potent selective PPARalpha modulator that may be safer than conventional agonists, but the efficacy of low-dose therapy in patients with type 2 diabetes and high triglyceride levels needed investigation.
Does low-dose pemafibrate improve lipid profiles in Japanese patients with type 2 diabetes and hypertriglyceridemia?
Observational (n=31)
No
Does low-dose pemafibrate improve lipid profiles in Japanese patients with type 2 diabetes and hypertriglyceridemia?
Mean Difference: 90.6 (95% CI 47.2–134.1)
Absolute Event Rate: 205.7% vs 296.9%
p-value: p=<0.001
Low-dose pemafibrate (0.1 mg/day) safely improves atherogenic lipid profiles in Japanese patients with type 2 diabetes and hypertriglyceridemia.
Low-dose pemafibrate was associated with favorable lipid shifts in type 2 diabetes; leaves open clinical adoption pending larger randomized trials.
INTRODUCTION: Pemafibrate is a potent selective peroxisome proliferator-activated receptor α (PPARα) modulator that may be safer than conventional PPARα agonists in the treatment of dyslipidemia. This study was designed to investigate the efficacy of low-dose pemafibrate (0.1 mg/day) therapy for hypertriglyceridemia in 31 patients with type 2 diabetes and high triglyceride (TG) levels at the Manda Memorial Hospital. METHODS: TG, remnant lipoprotein cholesterol (RLP-C), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein (Apo) AI, Apo AII, Apo B, Apo CII, Apo CIII, and Apo E levels were evaluated. Liver, kidney, and muscle toxicity tests were also performed. Pemafibrate (0.1 mg) was administered once daily. RESULTS: This treatment significantly decreased TG, RLP-C, Apo CII, Apo CIII, and Apo E levels while significantly increasing HDL-C, Apo AI, and Apo AII levels. No significant changes were observed in LDL-C and Apo B levels. There were no significant liver-, kidney-, or muscle-related adverse events. CONCLUSIONS: The results of this study show that low-dose pemafibrate administration improves the lipid profile in Japanese patients with hypertriglyceridemia and type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Bando et al. (2021) conducted an observational in Hypertriglyceridemia in Type 2 Diabetes (n=31). Pemafibrate vs. Baseline was evaluated on Change in Triglyceride (TG) levels (MD 90.6, 95% CI 47.2 to 134.1, p=<0.001). Low-dose pemafibrate (0.1 mg/day) significantly decreased triglyceride levels by a mean of 90.6 mg/dL compared to baseline in patients with type 2 diabetes and hypertriglyceridemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: